2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1814

Efficacy of Isoniazid Chemoprophylaxis in Lupus Nephritis Patients
Abstract Number: 1815

Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence
Abstract Number: 1816

Long-Term Outcome of Tacrolimus Therapy As a Maintenance Strategy in Patients with Lupus Nephritis
Abstract Number: 1817

Myocardial Tissue Characterization with Native Myocardial T1 Mapping in SLE Patients with Chest Pain
Abstract Number: 1818

Cyclophosphamide and Cumulative Steroid Dose Associated with Higher Risk of Infections in Patients with Lupus Nephritis
Abstract Number: 1819

Comparison of Electrocardiographic ST-T Changes and QTc Duration in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 1820

Prevalence and Risk-Factors for Asymptomatic Coronary-Artery Calcifications in Young Patients with Systemic Lupus Erythematosus
Abstract Number: 1821

Leptin, Adiponectin, and Resistin As Serum Markers of Fatigue in Systemic Lupus Erythematosus: A Pilot Study
Abstract Number: 1822

Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus Erythromatosus
Abstract Number: 1823

Visceral Adiposity in Premenopausal Lupus Patients: Correlation with Systemic Inflammation
Abstract Number: 1824

Tripterygium Wilfordii for the Treatment of Systemic Lupus Systematosus: Meta-Analysis of Randomized Controlled Trials
Abstract Number: 1825

Osteoprotegerin Is Associated with Lupus and with Coronary Artery Calcification
Abstract Number: 1826

Small LDL-P Increases with Increased Disease Activity in SLE
Abstract Number: 1827

Plasma Myeloperoxidase Levels Are Inversely Associated with Carotid Plaque in SLE
Abstract Number: 1828

Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].